Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTX vs LEXX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 2 LEXX (1 Tie) Matrix Metrics: ENTX 6 – 1 LEXX

As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas LEXX carries 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs LEXX
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 46% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 37.0 Fund 54.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.5 · SMA20: $3.09 · SMA50: $2.90
LEXX NASDAQ
Lexaria Bioscience Corp. Common Stock
Pharmaceutical Preparations
$4.41
-0.68% 1D
Market Cap $9.4M
TTM Revenue $194,000
Forward P/E N/M
Beta / 30D Vol 11.09β · 92% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.0 · SMA20: $3.78 · SMA50: $3.62

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 LEXX)

Columns: Metric · ENTX · LEXX
1. Valuation Multiples LEXX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 30.7x
2. Growth & Scale LEXX
Revenue Growth (YoY) -100.0% -88.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $194,000
Market Cap $541.6M $9.4M
3. Profitability & Quality ENTX
Gross Margin N/A 100.0%
Operating Margin 0.0% -3862.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -162.8%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$7.5M
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash $3.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 113.8% (32nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (6) vs LEXX (1)
Institutional Metric ENTX LEXX Criterion Row Edge
Market Capitalization
Scale
$541.6M $9.4M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -88.5% Higher Growth LEXX
Operating Margin (TTM)
Profitability
0.0% -3862.9% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -162.8% Higher ROE ENTX
52-Week Range Position
Momentum
64% ($1–$4) 29% ($0–$14) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
1.07β · 46% Vol 11.09β · 92% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
53.9 / 100 (HOLD) 33.3 / 100 (SELL) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $194,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 30.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$7.5M ($3.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LEXX +41.51 pp
ENTX: +12.69% · LEXX: +54.2%
3M Horizon ENTX +66.22 pp
ENTX: +4.5% · LEXX: -61.72%
6M Horizon LEXX +541.83 pp
ENTX: +145.53% · LEXX: +687.36%
1Y Horizon LEXX +290.69 pp
ENTX: +10.22% · LEXX: +300.91%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue LEXX Revenue ENTX Op. Margin LEXX Op. Margin Margin Leader
FY2018 N/A $0M N/A -1525.4% LEXX
FY2019 N/A $0M N/A -1868.0% LEXX
FY2020 $0M $0M -3059.7% -1062.2% LEXX
FY2021 $0M $0M -2139.6% -786.8% LEXX
FY2022 $0M $0M -9714.2% -2591.7% LEXX
FY2023 N/A $0M N/A -2888.5% LEXX
FY2024 $0M $0M -5295.6% -1239.2% LEXX
FY2025 $0M $0M -27450.0% -1683.0% LEXX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
79d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LEXX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LEXX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LEXX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.4M market capitalization and -3862.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs LEXX Key Questions & Quantitative Answers

As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas LEXX carries 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin). Technically, ENTX sits in a Neutral phase (RSI 49.5, CONSOLIDATION options structure) and LEXX sits in a Neutral phase (RSI 58.0, UNCLASSIFIED options structure).

LEXX leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LEXX at -88.5% YoY revenue growth and +0.0% YoY earnings growth on $194,000 TTM revenue (100.0% gross margin, -3862.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTX cumulative revenue shifted N/A while LEXX shifted N/A. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LEXX.

LEXX screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LEXX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus LEXX (-162.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk). By comparison, LEXX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.09β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.